Literature DB >> 33801202

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis.

Tomotake Shirono1, Takashi Niizeki1, Hideki Iwamoto1, Shigeo Shimose1, Hiroyuki Suzuki1, Takumi Kawaguchi1, Naoki Kamachi1, Yu Noda1, Shusuke Okamura1, Masahito Nakano1, Ryoko Kuromatu1, Hironori Koga1, Takuji Torimura1.   

Abstract

Prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is unsatisfactory. Tumor, host, and treatment factors including hepatic arterial infusion chemotherapy (HAIC) are intricately involved in the progression of ICC. We aimed to identify profiles associated with disease control rate (DCR) and the prognosis of patients with unresectable ICC by decision tree analysis. We analyzed 31 consecutive patients with unresectable ICC (median age, 71 years; the male ratio was 58.1%). Stage IVB occupied 51.6% of patients, and 38.7% and 58.1% of patients were treated with gemcitabine plus cisplatin combination therapy and HAIC, respectively. Profiles associated with prognosis as well as DCR were investigated by decision tree analysis. The median survival time (MST) of the patients was 11.6 months, and the DCR was 70.9%. Multivariate correlation analysis showed that albumin levels and WBC levels were significantly correlated with survival time (albumin, ρ = 0.3572, p = 0.0485; WBC, ρ = -0.4008, p = 0.0280). In decision tree analysis, WBC level was selected as the initial split variable, and subjects with WBC levels of 6800/μL or less (45.1%) showed a long survival time (MST 476 days). We also demonstrated that the profile associated with the highest DCR was "less than 4.46 mg/dL of CRP levels and treatment with HAIC". We demonstrated a new prognostic profile for ICC patients, which consisted of WBC and CRP levels. Moreover, we demonstrated that HAIC was associated with better disease control in ICC patients with low CPR levels. Thus, these new profiles may be useful for the management of ICC patients.

Entities:  

Keywords:  cholangiocarcinoma; inflammation; interventional radiology; prognostic variable; reservoir system

Year:  2021        PMID: 33801202      PMCID: PMC7957874          DOI: 10.3390/jcm10050987

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  44 in total

Review 1.  Current Status of Hepatic Arterial Infusion Chemotherapy.

Authors:  Shuntaro Obi; Shinpei Sato; Toshihiro Kawai
Journal:  Liver Cancer       Date:  2015-08-12       Impact factor: 11.740

2.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

3.  Construction the model on the breast cancer survival analysis use support vector machine, logistic regression and decision tree.

Authors:  Cheng-Min Chao; Ya-Wen Yu; Bor-Wen Cheng; Yao-Lung Kuo
Journal:  J Med Syst       Date:  2014-08-14       Impact factor: 4.460

4.  Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.

Authors:  Kazuhiro Kasai; Yohei Kooka; Yuji Suzuki; Akiko Suzuki; Takayoshi Oikawa; Akira Ushio; Yukiho Kasai; Kei Sawara; Yasuhiro Miyamoto; Kanta Oikawa; Yasuhiro Takikawa
Journal:  Ann Surg Oncol       Date:  2014-05-10       Impact factor: 5.344

5.  The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma.

Authors:  Stefan Buettner; Gaya Spolverato; Charles W Kimbrough; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Matthew Weiss; Todd W Bauer; Feng Shen; George A Poultsides; J Wallis Marsh; Jan N M IJzermans; Bas Groot Koerkamp; Timothy M Pawlik
Journal:  Surgery       Date:  2018-06-11       Impact factor: 3.982

6.  Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.

Authors:  Momar Diouf; Thomas Filleron; Anne-Laure Pointet; Anne-Claire Dupont-Gossard; David Malka; Pascal Artru; Mélanie Gauthier; Thierry Lecomte; Thomas Aparicio; Anne Thirot-Bidault; Céline Lobry; Francine Fein; Olivier Dubreuil; Bruno Landi; Aziz Zaanan; Julien Taieb; Franck Bonnetain
Journal:  Qual Life Res       Date:  2015-11-28       Impact factor: 4.147

7.  Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).

Authors:  Chigusa Morizane; Takuji Okusaka; Junki Mizusawa; Atsuo Takashima; Makoto Ueno; Masafumi Ikeda; Yasuo Hamamoto; Hiroshi Ishii; Narikazu Boku; Junji Furuse
Journal:  Cancer Sci       Date:  2013-07-25       Impact factor: 6.716

8.  Decision-tree approach to the immunophenotype-based prognosis of the B-cell chronic lymphocytic leukemia.

Authors:  N Masić; A Gagro; S Rabatić; A Sabioncello; G Dasić; B Jaksić; B Vitale
Journal:  Am J Hematol       Date:  1998-10       Impact factor: 10.047

Review 9.  Sample size: how many patients are necessary?

Authors:  P M Fayers; D Machin
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.

Authors:  Dingzhong Peng; Jiong Lu; Haijie Hu; Bei Li; Xiwen Ye; Nansheng Cheng
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

View more
  1 in total

1.  Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study.

Authors:  Tianxiao Wang; Jiahong Dong; Yuewei Zhang; Zhizhong Ren; Ying Liu; Xiaowei Yang; Dawei Sun; Yaqin Wang
Journal:  Ann Transl Med       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.